Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 23, 2017. The document serves as a transaction notification regarding dealings in the company's ordinary shares by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details a specific equity transaction.
| Metric | Value |
|---|---|
| Transaction Date | February 22, 2017 |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Shares Acquired (Exercise) | 29,931 |
| Exercise Price | £0.0000 (Nil-cost options) |
| Shares Sold (Tax Liability) | 14,352 |
| Average Sale Price | £16.3889 |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine equity event involving the Chief Financial Officer.
Management Commentary and Risks
The filing details the exercise of nil-cost options granted on February 12, 2014, under the 2009 Deferred Annual Bonus Plan. Specifically, Mr. S Dingemans, Chief Financial Officer, exercised options for 22,448 deferred shares and 7,483 matching shares. Subsequently, 10,763 deferred shares and 3,589 matching shares were sold on the London Stock Exchange to meet tax liabilities arising from the exercise. No other risks, contingencies, or guidance are provided in this text.
Investor Verification Checklist
- Verify the total number of shares held by Mr. S Dingemans post-transaction.
- Confirm the tax rate applied to the sale of shares to meet liabilities.
- Review the full terms of the 2009 Deferred Annual Bonus Plan for future vesting schedules.
- Check the London Stock Exchange (XLON) trading records for the specific execution prices on February 22, 2017.